Communiqués Tyra Biosciences, Inc.

Actions

TYRA

US90240B1061

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 21:59:51 22/09/2026			Varia. 5j.	Varia. 1 janv.
25,54 ^USD	-0,43%		+0,90%	-2,40%

15:25	Tyra Biosciences, Inc. : Opinion positive de Oppenheimer	ZM
14/09	L'action Tyra Bioscience progresse après l'annonce d'une augmentation de capital de 400 millions de dollars	MT

Communiqués

14/09	Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	PR
09/09	Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib	PR
08/09	Tyra Biosciences to Present at the Cantor Global Healthcare Conference	PR
04/09	Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026	PR
05/08	Tyra Biosciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
04/08	Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights	PR
21/05	TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY	PR
13/05	Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights	PR
07/05	Tyra Biosciences to Participate in Upcoming Investor Conferences	PR
20/04	Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors	AQ
17/04	Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors	PR
02/03	Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights	PR
23/02	Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium	PR
19/02	Tyra Biosciences to Participate in Upcoming Investor Conferences	PR
01/12	Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer	PR
12/11	Tyra Biosciences Announces Participation at Upcoming Investor Events	PR
05/11	Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights	PR
21/08/25	Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia	PR
20/08/25	Tyra Biosciences Announces Participation at Upcoming Investor Events	PR
14/08/25	Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights	PR
21/07/25	Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series	PR
08/07/25	Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025	PR
30/06/25	Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)	PR
12/05/25	Tyra Biosciences to Participate at Upcoming Investor Conferences	PR
08/05/25	Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights	PR